Nalidixic acid-resistant Salmonella enterica serotype typhi infection presenting with sub-intestinal obstruction and mesenteric adenitis.
Nalidixic acid-resistant Salmonella typhi NARST infections increase minimal inhibitory concentrations of fluoroquinolones, due to chromosomal mutations in the gene encoding DNA gyrase, and can lead to a delayed treatment response. This in turn alters the course of the disease allowing for a protracted period of illness and the occurrence of complications. In this case report, we present a patient from the Indian sub-continent, who was diagnosed with NARST complicated by sub-intestinal obstruction, her diagnosis, treatment, and subsequent recovery.
Al-Khuwaitir
Tarig S
TS
Department of Medicine, Division of General Internal Medicine, Riyadh Medical Complex, Ministry of Health, PO Box 3847, 11481 Riyadh, Kingdom of Saudi Arabia. khuwaitir@hotmail.com
Al-Zuhair
Amin A
AA
Al-Ghamdi
Ali G
AG
Khan
Abdulaziz
A
D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D007415:Intestinal Obstruction / Q000175:diagnosis / Q000382:microbiology*; D008640:Mesenteric Lymphadenitis / Q000175:diagnosis / Q000382:microbiology*; D009268:Nalidixic Acid / Q000627:therapeutic use; D012485:Salmonella typhi / Q000187:drug effects; D014435:Typhoid Fever / Q000175:diagnosis / Q000188:drug therapy*
D000890:Anti-Infective Agents; D009268:Nalidixic Acid; D002939:Ciprofloxacin